0098-OL:HK:HK-XINGFA ALUM (HKD)

COMMON STOCK | Other |

Last Closing

USD 7.72

Change

-0.30 (-3.74)%

Market Cap

N/A

Volume

0.09M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

There is no Profile data available for 0098-OL.HK. Address:

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-08 )

Largest Industry Peers for Other

Symbol Name Price(Change) Market Cap
1863:HK China Longevity Group Company ..

N/A

USD 1.17B
8355:HK I-CONTROL

N/A

USD 0.39B
8343:HK HongGuang Lighting Holdings Co..

-0.64 (-42.11%)

USD 0.31B
0648:HK CHINA RENJ

N/A

USD 0.12B
0182-OL:HK CHINA WINDPOWER

-0.07 (-11.11%)

N/A
0243-OL:HK QPL INT'L

-0.08 (-20.25%)

N/A
0259-OL:HK YEEBO (INT'L H)

-0.12 (-4.36%)

N/A
0187-OL:HK JINGCHENG MAC

-0.77 (-22.06%)

N/A
0272-OL:HK SHUI ON LAND

-0.15 (-16.85%)

N/A
0239-OL:HK PAK FAH YEOW

-0.03 (-1.21%)

N/A

ETFs Containing 0098-OL:HK

N/A

Market Performance

  Market Performance vs. Industry/Classification (Other) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 25.32% 67% D+ 69% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 25.32% 67% D+ 69% C-
Trailing 12 Months  
Capital Gain 5.03% 50% F 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.03% 50% F 53% F
Trailing 5 Years  
Capital Gain -0.26% 63% D 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.26% 63% D 63% D
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (HKD)

Quarterly Financials (HKD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike